Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

Seborrheic dermatitis (SD) is a prevalent, chronic relapsing inflammatory skin condition that affects patients of all ages, with a global prevalence of ≥ 5%. Patients suffering from SD typically develop pruritic, erythematous patches that feature easily detachable scales, primarily in…








